Part,  Chapter, Paragraph

 1    I,     2. 10.  5|      relative effectiveness and cost-effectiveness of new medical technologies.
 2   II,     5.  4.  6|       track health outcomes and cost-effectiveness, taking into account Member
 3   II,     5.  5.  3|        and colleagues evaluated cost-effectiveness of current and optimal treatment
 4   II,     5.  5.  3|  Issakidis C, Lapsley H (2003): Cost-effectiveness of current and optimal treatment
 5   II,     5.  5.  3| adjusted life years (DALYs): in cost-effectiveness analysis. Health Policy
 6   II,     5.  7.  5|          The Netherlands) and a cost-effectiveness analysis in support of this
 7   II,     5.  7.  7|         Gilst WH, et al (2006): Cost-effectiveness of screening for albuminuria
 8   II,     5.  7.  7|     proteinuria in US adults: a cost-effectiveness analysis. JAMA 2003;290(
 9   II,     5.  8.  4|     care towards prevention and cost-effectiveness of intervention (Mannino
10   II,     5. 14.  6|          This will optimize the cost-effectiveness ratio of the health programmes
11   II,     7.  4    |        of interventions and the cost-effectiveness of alternative interventions
12  III,    10.  2.  1|     shows the effectiveness and cost-effectiveness of opportunistic screening
13  III,    10.  2.  1|        of the effectiveness and cost-effectiveness of interventions delivered
14   IV,    11.  1.  5|         some notion of value or cost-effectiveness relative to alternative
15   IV,    11.  2.  2|  evaluate the effectiveness and cost-effectiveness of public health interventions.
16   IV,    11.  3.  2| Slovakia. In Germany and France cost-effectiveness analysis is used to inform
17   IV,    11.  4    |     methods such as~· Modelling cost-effectiveness ratios using quality-adjusted
18   IV,    11.  6.  4|       to assess evidence of the cost-effectiveness of health interventions,
19   IV,    11.  6.  4|       information regarding the cost-effectiveness of interventions is either
20   IV,    12.  2    |     shows the effectiveness and cost-effectiveness of opportunistic screening
21   IV,    13.  3    |  support decisions and evaluate cost-effectiveness of programmes represents
22   IV,    13.  3    |  evaluate the effectiveness and cost-effectiveness of public health intervention.